Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ambarella surges after report says company exploring strategic options, including sale (SeekingAlpha) +++ AMBARELLA Aktie +15,53%

ADVERUM Aktie

>ADVERUM Performance
1 Woche: 0%
1 Monat: +14,0%
3 Monate: -54,9%
6 Monate: -50,5%
1 Jahr: 0%
laufendes Jahr: -51,3%
>ADVERUM Aktie
Name:  ADVERUM BIOTECHNOLOGIES
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00773U2078 / A404YL
Symbol/ Ticker:  AVU0 (Frankfurt) / ADVM (NASDAQ)
Kürzel:  FRA:AVU0, ETR:AVU0, AVU0:GR, NASDAQ:ADVM
Index:  -
Webseite:  https://adverum.com/
Marktkapitalisierung:  47.02 Mio. EUR
Umsatz:  0.87 Mio. EUR
EBITDA:  -134.56 Mio. EUR
Gewinn je Aktie:  -5.449 EUR
Schulden:  80.97 Mio. EUR
Liquide Mittel:  72.2 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  52.91 / 2 / -
Gewinnm./ Eigenkapitalr.:  - / -144.51%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  ADVERUM
Letzte Datenerhebung:  24.06.25
>ADVERUM Eigentümer
Aktien: 20.89 Mio. St.
f.h. Aktien: 12.27 Mio. St.
Insider Eigner: 13.1%
Instit. Eigner: 79.49%
>ADVERUM Peer Group

 
05.06.25 - 22:06
 Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4)....
17.05.25 - 01:01
 Insiderhandel: CHIEF OPERATING OFFICER verkauft Aktien von Adverum Biotechnologies im Wert von 5920 USD (Insiderkauf)
 
Soparkar, Peter - Vorstand - Tag der Transaktion: 2025-05-15...
17.05.25 - 01:01
 Insiderhandel: CHIEF DEVELOPMENT OFFICER verkauft Aktien von Adverum Biotechnologies im Wert von 1848 USD (Insiderkauf)
 
Seyedkazemi, Setareh - Vorstand - Tag der Transaktion: 2025-05-15...
17.05.25 - 01:01
 Insiderhandel: CEO, PRESIDENT AND DIRECTOR verkauft Aktien von Adverum Biotechnologies im Wert von 18252 USD (Insiderkauf)
 
Fischer, Laurent - Vorstand - Tag der Transaktion: 2025-05-15...
14.05.25 - 23:54
 Adverum Biotechnologies GAAP EPS of -$2.25 misses by $0.31 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.25 - 22:03
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM (PR Newswire)
 
NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
02.05.25 - 22:03
 Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4)....
29.04.25 - 00:09
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM (PR Newswire)
 
NEW YORK, April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
24.04.25 - 20:01
 Insiderhandel: Insider kauft Aktien von Adverum Biotechnologies im Wert von 900000 USD (Insiderkauf)
 
Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-04-22...
24.04.25 - 20:01
 Insiderhandel: Insider kauft Aktien von Adverum Biotechnologies im Wert von 148950 USD (Insiderkauf)
 
Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-04-23...
22.04.25 - 22:01
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM (PR Newswire)
 
NEW YORK, April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
15.04.25 - 15:12
 ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, April 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ: ADVM) for violations of the securities......
15.04.25 - 13:51
 Adverum Biotechnologies GAAP EPS of -$1.96 misses by $0.60 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.04.25 - 13:42
 Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones (GlobeNewswire EN)
 
REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones....
15.04.25 - 00:21
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM (PR Newswire)
 
NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
04.04.25 - 22:06
 Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4)....
03.04.25 - 01:01
 Insiderhandel: Insider kauft Aktien von Adverum Biotechnologies im Wert von 85668 USD (Insiderkauf)
 
Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-03-31...
03.04.25 - 01:01
 Insiderhandel: Insider kauft Aktien von Adverum Biotechnologies im Wert von 61408 USD (Insiderkauf)
 
Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-04-02...
31.03.25 - 22:03
 Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire EN)
 
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET....
28.03.25 - 02:01
 Insiderhandel: Insider kauft Aktien von Adverum Biotechnologies im Wert von 102841 USD (Insiderkauf)
 
Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-03-26...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!